The I allele of the angiotensin-converting enzyme gene polymorphism may determine an increase in homocysteine levels in fibrate-treated subjects

Cardiovascular Drugs and Therapy

Volumn 20, Issue 3, 2006, Pages 229-232

  Potaczek, Daniel P ^a   Undas, Anetta ^a   Celinska Lowenhoff, Magdalena ^a   Szczeklik, Andrew ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Fenofibrate; Genetics; Homocysteine; Simvastatin

Indexed keywords

C REACTIVE PROTEIN; CD40 LIGAND; CELL ADHESION MOLECULE; DIPEPTIDYL CARBOXYPEPTIDASE; FENOFIBRATE; FENOFIBRATE SUPRA; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; SIMVASTATIN;

ADULT; ALLELE; AMINO ACID BLOOD LEVEL; ARTICLE; BLOOD CHEMISTRY; CARDIOVASCULAR RISK; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE PREDISPOSITION; DRUG EFFECT; DRUG POTENCY; FEMALE; GENE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HETEROZYGOTE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; PRIORITY JOURNAL; RISK REDUCTION; STATISTICAL SIGNIFICANCE;

ALLELES; ANTILIPEMIC AGENTS; FEMALE; FENOFIBRATE; GENOTYPE; HOMOCYSTEINE; HUMANS; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC; PROCETOFEN; SIMVASTATIN;

EID: 33746218022     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-006-8374-8     Document Type: Article

References (15)

1. Chapman MJ. Beyond the statins: new therapeutic perspectives in cardiovascular disease prevention. Cardiovasc Drugs Ther 2005;19:135-9.
2. Cignarella A, Bolego C, Paoletti R. Impact of statins on novel risk markers. Cardiovasc Drugs Ther 2003;17:361-6.
3. Ushiroyama T, Ikeda A, Higashio S, Ueki M. Coagulofibrinolytic assessment of effects of bezafibrate on hypertriglyceridemia in postmenopausal women. Blood Coagul Fibrinolysis 2000;11:709-14.
4. Musial J, Undas A, Gajewski P, Jankowski M, Sydor W, Szczeklik A. Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. Int J Cardiol 2001;77:247-53.
5. Šebaštjen M, Keber I, Žegura B, et al. Statin and fibrate treatment of combined hyperlipidaemia: the effects on some novel risk factors. Thromb Haemost 2004;92:1129-35.
6. Milionis HJ, Papakostas J, Kakafika A, Chasiotis G, Seferiadis K, Elisaf MS. Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia. J Clin Pharmacol 2003;43:825-30.
7. Dierkes J, Westphal S, Kunstmann S, Banditt P, Lössner A, Luley C. Vitamin supplementation can markedly reduce the homocysteine elevation induced by fenofibrate. Atherosclerosis 2001;158:161-4.
8. Rolland PH, Friggi A, Barlatier A, et al. Hyperhomocysteinemia-induced vascular damage in the minipig. Captopril-hydrochlorothiazide combination prevents elastic alterations. Circulation 1995;91:1161-74.
9. Fu YF, Xiong Y, Fu SH. Captopril restores endothelium-dependent relaxation of rat aortic rings after exposure to homocysteine. J Cardiovasc Pharmacol 2003;42:566-72.
10. Marian AJ, Safavi F, Ferlic L, Dunn JK, Gotto AM, Ballantyne CM. Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response to plasma lipids and coronary atherosclerosis to treatment with fluvastatin. J Am Coll Cardiol 2000;35:89-95.
11. Maitland-van der Zee AH, Stricker BHCh, Klungel OH, et al. Effectiveness of HMG-CoA reductase inhibitors is modified by the ACE insertion deletion polymorphism. Atherosclerosis 2004;175:377-9.
12. Potaczek DP, Undas A, Iwaniec T, Szczeklik A. The angiotensin-converting enzyme gene insertion/deletion polymorphism and effects of quinapril and atorvastatin on haemostatic parameters in patients with coronary artery disease. Thromb Haemost 2005;94:224-5.
13. Bossé Y, Vohl MC, Dumont M, et al. Influence of the angiotensin-converting enzyme gene insertion/deletion polymorphism on lipoprotein/lipid response to gemfibrozil. Clin Genet 2002;62:45-52.
14. Mansoor MA, Svardal AM, Ueland PM. Determination of the in vivo redox status of cysteine, cysteinylglycine, homocysteine, and glutathione in human plasma. Anal Biochem 1992;200:218-29.
15. Graham IM, O'Callaghan P. Vitamins, homocysteine and cardiovascular risk. Cardiovasc Drugs Ther 2002;16:383-9.